Bristol-Myers' $74B Celgene Buy Gives 2019 M&A Fast Start
By Chelsea Naso ( January 3, 2019, 7:16 PM EST) -- Deal-making roared just three days into the New Year as Bristol-Myers Squibb's $74 billion cash-and-stock megadeal for biopharmaceutical company Celgene carried a price tag bigger than last year's largest deal despite recent market volatility....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.